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Background: Lipocalin-2 is induced in obesity/type 2 diabetes.
Results: TNF and IFN induce LCN2 in vivo. STAT1 and NF-B are required for LCN2 induction and bind the human LCN2
promoter.
Conclusion: An interplay between ERKs, STAT1, and NF-B signaling pathways mediates the IFN and TNF induction of
LCN2.
Significance: Cytokine modulation of LCN2 increases our understanding of gene regulation in obesity/type 2 diabetes.
Lipocalin-2 (LCN2) is secreted from adipocytes, and its
expression is up-regulated in obese and diabetic mice and
humans. LCN2 expression and secretion have been shown to be
induced by two proinflammatory cytokines, IFN and TNF, in
cultured murine and human adipocytes. In these studies, we
demonstrated that IFN and TNF induced LCN2 expression
and secretion in vivo. Although we observed a strong induction
of LCN2 expression and secretion from white adipose tissue
(WAT) depots, the induction of LCN2 varied among different
insulin-sensitive tissues. Knockdown experiments also demon-
strated that STAT1 is required for IFN-induced lipocalin-2
expression in murine adipocytes. Similarly, knockdown of p65
in adipocytes demonstrated the necessity of the NF-B signaling
pathway for TNF-mediated effects on LCN2. Activation of
ERKs by IFN and TNF also affected STAT1 and NF-B sig-
naling through modulation of serine phosphorylation. ERK acti-
vation-induced serine phosphorylation of both STAT1 and p65
mediated the additive effects of IFN and TNF on LCN2
expression. Our results suggest that these same mechanisms
occur in humans as we observed STAT1 and NF-B binding to
the human LCN2 promoter in chromatin immunoprecipitation
assays performed in human fat cells. These studies substantially
increase our knowledge regarding the requirements and mech-
anisms used by proinflammatory cytokines to induce LCN2
expression.
Adipose tissue produces cytokines and hormones that mod-
ulate energy metabolism and systematic insulin sensitivity (1).
Alterations in expression or secretion of these secreted proteins
from adipocytes can contribute to insulin resistance. Chronic
inflammation accompanied by immune cell infiltration into
adipose tissue has been shown to play an important role in the
pathogenesis of insulin resistance (2, 3). Proinflammatory cyto-
kines secreted by adipose tissue immune cells can affect prop-
erties of adipocytes. Two major proinflammatory cytokines,
IFN and TNF, can induce insulin resistance in adipocytes
(4 –7) and modulate the expression and secretion of adipokines
(8 –10), including adiponectin (9, 11), which is exclusively
expressed in mature adipocytes.
Lipocalin-2 (LCN2)2 belongs to the lipocalin family, a group
of well known transporters of small hydrophobic molecules in
circulation (12). LCN2 was initially characterized as a protein
that interacts with and stabilizes matrix metalloproteinase 9
(13). LCN2 plays important roles in innate immune response by
limiting bacterial growth (14 –16). More recent studies have
shown that LCN2 is a novel adipokine that is up-regulated in
obese and type 2 diabetic subjects (17). However, the roles of
LCN2 in modulating insulin sensitivity are still unclear. Studies
of global LCN2 knock-out mice from separate groups have
reported divergent phenotypes (18 –20). Given the versatile
functions of LCN2, it is not surprising that the phenotypes of
global knock-out mice are inconsistent. Although the role of
LCN2 in modulation of insulin action is not clear, it is clear that
LCN2 is produced in adipocytes and regulated in murine and
human obesity (17, 21, 22). In one study, administration of
LCN2 induced peroxisome proliferator-activated receptor 
and adiponectin expression and ameliorated the negative
effects of TNF in 3T3-L1 adipocytes (23). Recently, LCN2 has
been shown to be highly expressed in inguinal fat and to signif-
icantly affect high fat diet-induced adipose tissue expandability
in a depot-specific manner (24). In this study, the absence of
LCN2 expression significantly enhanced high fat diet-induced
inguinal fat expansion. However, compared with wild type
mice, high fat diet-induced epididymal fat expansion in LCN2-
deficient mice was significantly decreased (24). Although some
observations suggest a potentially metabolically protective role
of LCN2, there are substantial inconsistent observations related
to actions of LCN2 in relation to glucose tolerance and insulin
sensitivity (18 –20).
Despite the positive correlations of expression and circulat-
ing levels of LCN2 with obesity and insulin resistance (21, 22),* This work was supported, in whole or in part, by National Institutes of Health
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the underlying mechanism mediating the induction of LCN2 is
still unknown. Here, we report that IFN and TNF induce
LCN2 expression and secretion in vivo. Using knockdown
methodology, we showed that STAT1 and NF-B are required
for the induction of LCN2 by proinflammatory cytokines. Our
previous observations demonstrated that ERK signaling also
contributes to the IFN- and TNF-induced expression of
LCN2 (25). Our new results reveal that ERK 1 and 2 activation
affects the serine phosphorylation of STAT1 and NF-B at spe-
cific sites. These studies suggest that STAT1Ser727 phosphory-
lation plays a role in the additive effects of IFN and TNF on
LCN2 expression in adipocytes. Moreover, we identified sev-
eral STAT1 and NF-B binding sites in the human LCN2 pro-
moter, suggesting some translational relevance to our mecha-
nistic studies. Collectively, our data demonstrate that IFN and
TNF are capable of inducing LCN2 from several insulin-sen-
sitive tissues in vivo and provide insight into the interplay
between ERKs and STAT1 or NF-B signaling pathways in
adipocytes.
EXPERIMENTAL PROCEDURES
Animals—Procedures for animal studies were approved by
the Pennington Biomedical Research Center Institutional Ani-
mal Care and Use Committee. Adult male C57BL/6J mice were
purchased from The Jackson Laboratory. All mice were housed
in groups of three or four and had free access to water and
standard chow (Purina LabDiet 5001). IFN and TNF (R&D
Systems) were dissolved in a sterile PBS with 0.1% BSA vehicle
solution. 10-Week-old male mice (25 g) were injected intra-
peritoneally with 0.2 ml of vehicle, IFN (1.25 mg/kg of body
weight), TNF (0.05 mg/kg of body weight), or both cytokines.
Mice were euthanized by CO2 gas inhalation 3 or 14 h postin-
jection. Tissues were removed, immediately frozen in liquid
nitrogen, and stored at 80 °C. Blood was collected into serum
separator tubes, allowed to clot at room temperature, and cen-
trifuged at 1500  g for 15 min at 4 °C. The supernatant (serum)
was then transferred to a clean tube and stored at 80 °C for
later analysis.
Cell Culture—Murine 3T3-L1 preadipocytes were grown in
Dulbecco’s modified Eagle’s medium (DMEM) containing 10%
bovine serum. Two days after confluence, a mixture of 0.5
mmol/liter 3-isobutyl-methylxanthine, 1 mol/liter dexameth-
asone, and 1.7 mol/liter insulin was added to induce preadi-
pocyte differentiation in DMEM with 10% fetal bovine serum
(FBS). Medium was changed by DMEM with 10% FBS 48 h
later. DMEM was from Sigma. Bovine serum and FBS were
from Hyclone. Human subcutaneous adipocytes in 6-well
plates were from Zen-Bio. Recombinant mouse and human
IFN was purchased from R&D Systems. Recombinant mouse
and human TNF was purchased from Invitrogen. UO126 was
purchased from Promega.
Small Interfering RNA-mediated Knockdown—3T3-L1 adi-
pocytes were trypsinized and replated in 24-well plates. Cells
were transfected using DharmaFECT Duo (Thermo-Dharma-
con) reagent and 100 nM siRNA (Thermo-Dharmacon; Non-
targeting siRNA, catalog number D-001810-10-50; STAT1
siRNA, catalog number L-058881-00-0020; p65 siRNA, catalog
number L-040776-00-0020). Non-targeting siRNA was used as
a negative control. After 24 h, cells were harvested for RNA
analysis and assessment of transfection efficiency.
RNA Analysis—Tissues were homogenized in TRIzol
(Qiagen). Cell monolayers were harvested in RLT lysis buffer.
Total RNA was isolated from homogenized tissues or harvested
cells with an RNeasy mini kit (Qiagen). 10 l of purified RNA
was used for reverse transcription-PCR to generate cDNA.
Ct real time PCR with SYBR Green Supermix reagent
(Takara) and an Applied Biosystems 7900HT system were used
to analyze cDNA. Cyclophilin A was used as an endogenous
control. The following primers were used for real time PCR:
mCyclophilin A: forward, CCACTGTCGCTTTTCGCCGC;
reverse, TGCAAACAGCTCGAAGGAGACGC; mLipocalin-2:
forward, TGCAAGTGGCCACCACGGAG; reverse, GCATT-
GGTCGGTGGGGACAGAGA.
Preparation of Whole Cell Extracts—3T3-L1 adipocytes were
harvested in non-denaturing IP buffer containing 10 mmol/
liter Tris (pH 7.4), 150 mmol/liter NaCl, 1 mmol/liter EGTA, 1
mmol/liter EDTA, 1% Triton X-100, and 0.5% Nonidet P-40
with protease inhibitors 1 mol/liter phenylmethylsulfonyl fluo-
ride, 1 mol/liter pepstatin, 50 milliunits of trypsin inhibitory
aprotinin, and 10 mol/liter leupeptin and phosphatase inhib-
itor 2 mmol/liter sodium vanadate. Cell monolayers were
scraped off the plates. Each extract was needled three times and
centrifuged at 9500  g for 10 min at 4 °C. Supernatants were
then transferred to new tubes and analyzed with BCA (Pierce)
to measure protein concentration.
Gel Electrophoresis and Immunoblotting—Proteins were sep-
arated on 7.5 or 10% gels by SDS-PAGE and transferred to
nitrocellulose membranes. Membranes were blocked in 4%
milk for 1 h and then incubated with primary antibody over-
night at 4 °C. After incubation with HRP-conjugated secondary
antibodies (Jackson ImmunoResearch Laboratories), enhanced
chemiluminescence reagents (Pierce) were used to visualize
results. The lipocalin-2 antibody was purchased from R&D Sys-
tems. ERK1/2, STAT5A, and p65Ser276 antibodies were from
Santa Cruz Bioechnology. The adiponectin antibody was from
Thermo-Pierce. STAT1, STAT1Tyr701, STAT1Ser727, STAT5,
p65, p65Ser536, and MCP-1 antibodies were from Cell Signaling
Technology. The active ERK1/2 antibody was from Promega.
Chromatin Immunoprecipitation (ChIP)—A SimpleChIP
enzymatic chromatin IP kit (Cell Signaling Technology) was
used for the ChIP assay. Human subcutaneous adipocytes were
serum-deprived overnight. Cells were treated with recombi-
nant human cytokines for 30 min and then cross-linked with
formaldehyde and glycine. Chromatin extracts were prepared
according to the manufacturer’s protocol. STAT1 and p65 anti-
bodies for immunoprecipitation were purchased from Cell Sig-
naling Technology. Purified DNA was quantified by real time
PCR with SYBR Green Supermix and ROX buffer (Takara).
Primer sequences for real time PCR were as follows: 176: for-
ward, GAAACAGCACAAGGAAGGCACAGA; reverse, CCT-
GCGGAAACACTTGGCAAGATT; 856: forward, ATAAC-
TGCTTCCCTGCTGGACAAG; reverse, GGCCTTATCCTT-
GAGGTCACTGAG; 1405: forward, CGGCCTGGCAGAG-
GATACTTTTTA; reverse, GTTGCACCAAAGCCTTCCCT-
TTCT; 1934: forward, GCCTCCCAGGTTCAAGCAATT-
CTT; reverse, CAAAGATTAGTTGGGCATGGTGGC;
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3610: forward, CCACGCTGAACACTACTCACAAGA; re-
verse, TGCATGAAGGCAGCAAGATGCTTC. The formula
used to calculate the percentage of input was as follows: Perc-
entage of input  2%  2(C[T] 2% input sample  C[T] IP sample).
Adipose Tissue Explant Culture—Epididymal WAT and
inguinal WAT (100 mg/well) were dissected, weighed, minced,
and cultured in 6-well plates with low glucose DMEM contain-
ing 1% FBS. Minced tissues were treated or untreated with 0.5
nM TNF. Total RNA was isolated after 3 h and analyzed by real
time PCR.
Statistical Analysis—All data were analyzed by two-tailed
unpaired Student’s t test. Data from the animal experiments are
presented as mean  S.E. Results from studies of cultured adi-
pocytes and ex vivo adipose tissues are shown as mean  S.D.
Results were considered statistically significant when p  0.05
(#, p  0.1; *, p  0.05; **, p  0.01; ***, p  0.001 versus control).
RESULTS
Lipocalin-2 Expression and Secretion Are Induced by Proin-
flammatory Cytokines in Vivo—Several studies have shown that
LCN2 is induced in obesity/type 2 diabetes mellitus (17, 21, 22),
and we have shown that both IFN and TNF induce LCN2 in
cultured murine and human adipocytes (25). However, the abil-
ity of these cytokines to induce LCN2 in the whole animal has
not been investigated. To determine the ability of these cyto-
kines to modulate LCN2 in vivo, 10-week-old male C57BL/6J
mice were injected intraperitoneally with IFN or TNF. After
14 h, the mice were sacrificed, and epididymal fat pads were
collected. As shown in Fig. 1A, both IFN and TNF increased
LCN2 mRNA levels in epididymal WAT. To determine
whether these cytokines could modulate circulating levels of
LCN2, we also collected serum from these mice. As shown in
Fig. 1B, IFN and TNF increased circulating levels of LCN2.
LCN2 is an adipokine but is also known to be expressed in
other tissues. Therefore, we examined the ability of IFN and
TNF to induce LCN2 expression in other insulin-sensitive
tissues. In this experiment, C57BL/6J mice were injected intra-
peritoneally with IFN, TNF, or both of these cytokines. Our
previous studies demonstrated that IFN and TNF had an
additive effect on the induction of LCN2 in cultured adipocytes
(25). As shown in Fig. 2, treatments with IFN, TNF, and the
combination of both cytokines significantly induced LCN2
expression in epididymal WAT (Fig. 2A), liver (Fig. 2C), and
heart (Fig. 2D) 3 h after cytokine injection. The combination of
both cytokines caused a more robust elevation of LCN2 mRNA
and provides novel data demonstrating that IFN and TNF
have additive effects on LCN2 expression in vivo. Treatment
FIGURE 1. IFN and TNF induce lipocalin-2 expression and secretion in vivo. 10-Week-old male C57BL/6J mice were injected intraperitoneally with IFN
(1.25 mg/kg of body weight) or TNF (0.05 mg/kg of body weight) and euthanized 14 h later. A, total RNA in epididymal WAT was purified and analyzed by real
time PCR. Cyclophilin A (PPIA) was used as an endogenous control. B, 250 g of serum protein was subjected to Western blot analysis. Western blot results were
quantified with ImageJ. The quantification is in the bottom panel. Data are shown as mean  S.E., n  4 mice/condition. *, p  0.05; **, p  0.01; ***, p  0.001.
Error bars represent S.E. AU, arbitrary units.
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with either IFN or TNF did not significantly induce LCN2
expression in inguinal WAT (Fig. 2B) or medial gastrocnemius
(Fig. 2E). However, the combination treatment did significantly
increase LCN2 in both of these tissues. As shown in Table 1,
epididymal WAT is the tissue that primarily responds to IFN
treatment as indicated by an increase in the LCN2 mRNA level
of 15-fold. However, liver was the most sensitive to TNF
treatment, which resulted in an elevation of LCN2 mRNA levels
by more than 2000-fold. Collectively, these experiments indi-
cate that IFN and TNF differentially modulate LCN2 expres-
sion in a tissue-specific manner and have additive effects in
vivo.
To determine whether the site of injection contributed to the
different responses of epididymal WAT and inguinal WAT, we
dissected both adipose tissues depots from the same mouse and
treated them with TNF or vehicle in ex vivo experiments. As
shown in Fig. 2F, expression of LCN2 increased by 8-fold in
epididymal WAT but only by 3-fold in inguinal WAT following
FIGURE 2. IFN and TNF differentially induce lipocalin-2 expression in different tissues. 10-Week-old male C57BL/6J mice were injected intraperitoneally
with IFN (1.25 mg/kg of body weight), TNF (0.05 mg/kg of body weight), or both (Combo) and euthanized 3 h later. Total RNA in epididymal WAT (A), inguinal
WAT (B), liver (C), heart (D), and gastrocnemius (E) was isolated and analyzed by real time PCR. Cyclophilin A (PPIA) was used as an endogenous control. Data are
presented as mean  S.E., n  3 mice/condition. F, 100 mg of epididymal WAT and inguinal WAT from 9-week-old male C57BL/6J mice was treated with 0.5 nM
TNF for 3 h. Total RNA was isolated and analyzed by real time PCR. Cyclophilin A was used as an endogenous control. For each tissue, the results were
normalized to the control condition. The figure is representative of an experiment performed three times on at least two mice. Error bars represent S.D. #, p 
0.1; *, p  0.05; **, p  0.01; ***, p  0.001. AU, arbitrary units.
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TNF treatment. This observation suggests that proinflamma-
tory cytokines regulate LCN2 expression in a tissue-dependent
manner. However, the results also demonstrate that TNF can
significantly induce LCN2 expression in inguinal WAT. Con-
sidering our observation that intraperitoneal injection of TNF
did not significantly induce LCN2 expression in inguinal WAT
(Fig. 2B), these ex vivo studies indicate that the site of injection
can contribute to the response of proinflammatory cytokines in
inguinal WAT.
NF-B Is Required for TNF-induced Lipocalin-2 Expression—
Recent studies by our laboratory have shown that TNF-in-
duced NF-B activation results in binding of p65 to one site in
the murine LCN2 promoter and correlates with the induction
of LCN2 expression (25). To determine the importance of
NF-B signaling in the ability of TNF to induce LCN2 expres-
sion in adipocytes, we used a knockdown approach. Small inter-
fering RNA targeting the p65 subunit of NF-B was transfected
into mature 3T3-L1 adipocytes. As shown in Fig. 3A, p65
mRNA levels were reduced by 60 –70% with p65 siRNA trans-
fection. Non-targeting siRNA was used as a negative control
and had no effect on p65 mRNA expression. Two days after
transfection, adipocytes were serum-deprived overnight and
then treated with TNF for 16 (for RNA analysis) or 24 h (for
protein analysis). As expected, TNF induced LCN2 mRNA
and protein in control adipocytes and in adipocytes transfected
with non-targeting siRNA. However, the ability of TNF to
induce LCN2 mRNA (Fig. 3B) and protein (Fig. 3C) was sub-
stantially reduced in cells transfected with p65 siRNA. STAT5A
was used as a protein loading control. We also examined the
expression level of MCP-1, an inflammatory marker that can be
induced by TNF and secreted by adipocytes. The TNF-me-
diated induction of MCP-1 was also substantially decreased by
p65 knockdown.
STAT1 Is Required for IFN-induced Lipocalin-2 Expression—
Our recent studies have also shown that IFN-induced LCN2
expression correlates with the binding of STAT1 to five sites in
the murine LCN2 promoter (25). To determine whether IFN-
activated STAT1 was required for the induction of LCN2 in
adipocytes, we used an siRNA knockdown approach. STAT1
mRNA was decreased by 60% with STAT1 knockdown (Fig.
4A). Transfection of non-targeting siRNA had no effect on the
STAT1 mRNA level. Two days after transfection, mature adi-
pocytes were serum-deprived and treated with IFN for 16 (for
RNA analysis) or 24 h (for protein analysis). As reported previ-
ously, IFN treatment induced LCN2 mRNA (Fig. 4B) and pro-
tein levels (Fig. 4C) in 3T3-L1 adipocytes. Moreover, the induc-
tion of LCN2 was significantly reduced in adipocytes that had
less STAT1. STAT1 knockdown had no effect on STAT5 pro-
teins in adipocytes (Fig. 4C). It is known that IFN can induce
MCP-1 in human mesangial cells (26); we observed a similar
induction of MCP-1 in 3T3-L1 adipocytes following IFN
treatment. However, STAT1 knockdown did not affect IFN-
induced MCP-1 expression.
TNF- and IFN-induced ERK Signaling Modulates the Ser-
ine Phosphorylation of STAT1 and p65—Our recent studies on
LCN2 have shown that the induction of this adipokine by both
IFN and TNF is dependent on ERK activation (25). Hence,
we wanted to investigate how ERK signaling contributes to the
effects of these cytokines. There is evidence to suggest that ser-
ine phosphorylation of NF-B (27–29) and STAT 1 (30, 31)
plays a role in the transcriptional activity of these signaling pro-
teins. Therefore, we examined the phosphorylation of STAT1
at Ser727 and p65 at Ser536 to determine the effects of IFN or
TNF treatment on phosphorylation. Fully differentiated
3T3-L1 adipocytes were acutely treated (15 min) with IFN,
TNF, or both cytokines. As shown in Fig. 5A, IFN and TNF
activated the ERK 1 and 2 signaling pathways in adipocytes. Of
note, TNF treatment in the presence or absence of IFN
induced phosphorylation of Ser536 on p65. However, IFN did
not modulate p65 serine phosphorylation at this site. IFN did
induce STAT1 tyrosine phosphorylation. All treatments
induced STAT1Ser727 phosphorylation. The data clearly indi-
cate an additive effect of IFN and TNF on STAT1Ser727
phosphorylation.
NF-B signaling studies have also revealed that p65 can be
phosphorylated on Ser276 by activation of PKA (29). Therefore,
we also examined p65Ser276 phosphorylation. Forskolin, a PKA
activator, was used as a positive control in these experiments.
As shown in Fig. 5B, neither IFN nor TNF had an effect on
p65Ser276. Nonetheless, we examined the ability of p65Ser276
phosphorylation to influence LCN2 expression. Mature adi-
pocytes were treated with TNF or forskolin for 16 h. TNF
induced LCN2 expression, whereas forskolin decreased LCN2
expression (Fig. 5C). These results suggest that phosphoryla-
tion of p65Ser276 does not participate in the induction of LCN2
expression.
Because our results suggested that serine phosphorylation
may play a role in the additive effects of TNF or IFN on LCN2
expression, we assessed whether the activation of ERKs was
required for serine phosphorylation of p65 and STAT1. Mature
3T3-L1 adipocytes were pretreated with the highly specific ERK
inhibitor UO126 for 30 min and then exposed to TNF or IFN
for an additional 15 min. As expected, ERK activation was
inhibited by UO126 pretreatment. We observed that TNF-
induced p65Ser536 phosphorylation was eliminated by inhi-
bition of ERKs (Fig. 6A). These data suggest that ERKs
directly mediate Ser536 phosphorylation of p65. Although
UO126 pretreatment had no effect on IFN-induced STAT1
tyrosine phosphorylation, both IFN- and TNF-induced
serine phosphorylation of STAT1 was abolished by ERK
inhibition (Fig. 6B).
Identification of STAT1 and NF-B Binding Sites in Human
LCN2 Promoter—As indicated above, our recent efforts have
identified one NF-B and several STAT1 binding sites in the
TABLE 1
IFN and TNF induced lipocalin-2 expression in different tissues
-Fold
IFN TNF IFN  TNF
Epididymal WAT 17a 26a 86b
Inguinal WAT n.s.c n.s.d (p  0.0875) 44a
Liver 7e 2175e 4527a
Heart 3e 14b 67b
Gastrocnemius n.s. n.s. 9a
ap  0.01.
b p  0.001.
c n.s., not significant.
d p  0.1.
e p  0.05.
Mechanisms Involved in Lipocalin-2 Expression
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murine LCN2 promoter (25). Hence, we performed an in silico
analysis to identify potential STAT1 and NF-B binding sites in
human LCN2 promoter (Table 2). The four potential STAT1
binding sites and one potential NF-B binding site were exam-
ined by ChIP assays. Human subcutaneous adipocytes were
treated with recombinant human IFN or TNF for 30 min.
ChIP assays were performed with specific STAT1 and p65 anti-
bodies. As shown in Fig. 7A, we observed that all four potential
STAT binding sites were capable of interacting with STAT1 in
an IFN-induced manner in human fat cells in vivo. In addition,
we observed TNF-induced p65 binding to an NF-B binding
site in the human LCN2 promoter in human adipocytes (Fig.
7B). These results are consistent with our previous observations
that demonstrate that IFN or TNF can induce LCN2 expres-
sion in human subcutaneous adipocytes (25).
DISCUSSION
Chronic inflammation in adipose tissue is associated with
insulin resistance (2, 3). Proinflammatory cytokines secreted by
immune cells present in adipose tissue can affect the function of
adipocytes, including insulin sensitivity and endocrine func-
tions. The adipokine LCN2 is significantly elevated in obese and
diabetic subjects (21, 22), and studies in animal models demon-
strate increased LCN2 in the adipose tissue of ob/ob and db/db
mice (17). Despite the profound induction of LCN2 in obesity in
mice and man, the underlying mechanisms mediating these
FIGURE 3. NF-B is required for TNF-induced lipocalin-2 expression in adipocytes. 3T3-L1 adipocytes were transfected with 100 nM non-targeting siRNA
or p65 siRNA. A, 24 h later, total RNA was purified and analyzed by real time PCR. B, after 40 h, cells were serum-deprived for 24 h and treated with 0.5 nM TNF.
Total RNA was isolated 16 h later and subjected to quantitative real time PCR. Cyclophilin A (PPIA) was used as an endogenous control. C, 40 h after transfection,
adipocytes were serum-deprived for 24 h and treated with 0.5 nM TNF. Whole cell extract was harvested after 24 h, and 150 g of protein was analyzed by
Western blot. Western blots were quantified with ImageJ. Data are from representative experiments that were independently performed three times. ***, p 
0.001; n.s., not significant. Error bars represent S.D. AU, arbitrary units; CTL, control; NT, non-targeting; KD, knockdown.
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effects are largely unknown. Our studies show that IFN and
TNF are able to induce LCN2 expression in vitro (25), and we
have now demonstrated profound modulation of LCN2 in vivo.
We observed that IFN and TNF induced LCN2 in the pri-
mary insulin-sensitive tissues: adipose tissue, skeletal muscle,
and liver. These studies also provide the first in vivo evidence to
support the hypothesis that immune cell-derived inflammatory
cytokines may be responsible for the increase of LCN2 expres-
sion in obesity and type 2 diabetes. Our studies also revealed
tissue-specific responses. IFN treatment affected LCN2
expression primarily in epididymal WAT, whereas LCN2 mod-
ulation in liver was most sensitive to TNF. We did not observe
a significant increase of LCN2 in inguinal WAT or gastrocne-
mius in mice treated with IFN or TNF. However, there was a
significant cooperative effect of IFN and TNF on LCN2
induction in most tissues examined. These are the first studies
to demonstrate such an effect in vivo. In our studies, we deliv-
ered cytokines via intraperitoneal injection. Because inguinal
WAT and gastrocnemius are not in the abdominal cavity, the
lack of response in these tissues could be due to their physical
distance from the injection site, which may lead to limited
responsiveness to this specific method of cytokine treatment.
We predicted that intravenous administration of the cytokines
could produce different responses in these two tissues. The
results from our ex vivo experiments clearly show that TNF
induced LCN2 expression in a fat depot-specific manner.
Nonetheless, the significant up-regulation of LCN2 in TNF-
treated inguinal WAT that we observed ex vivo suggests that
the injection site likely contributed to the lack of TNF
response in inguinal fat in our whole animal studies.
FIGURE 4. STAT1 is necessary for IFN-induced lipocalin-2 expression in adipocytes. 3T3-L1 adipocytes were transfected with 100 nM STAT1 siRNA or
non-targeting siRNA. A, 24 h later, total RNA was purified and analyzed by real time PCR. B, after 40 h, cells were serum-deprived for 24 h and treated with 100
ng/ml IFN. Total RNA was isolated 16 h later and subjected to quantitative real time PCR. Cyclophilin A (PPIA) was used as an endogenous control. C, 40 h after
transfection, adipocytes were serum-deprived for 24 h and treated with 100 ng/ml IFN. Whole cell extracts were obtained after 24 h, and 150 g of protein was
analyzed by Western blot. Western blots were quantified with ImageJ. Each panel is representative of an experiment that was independently performed three
times. ***, p  0.001. Error bars represent S.D. AU, arbitrary units; CTL, control; NT, non-targeting; KD, knockdown.
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Our previous studies suggested that STAT1 mediates IFN-
induced LCN2 expression and that NF-B plays a role in
TNF-mediated induction of LCN2 in cultured adipocytes
(25). However, both of these cytokines activate other signaling
pathways, so we investigated the dependence on STAT1 or the
p65 subunit of NF-B by performing siRNA-mediated knock-
down of these two transcription factors. Our results demonstrated
that STAT1 knockdown significantly attenuated IFN-induced
LCN2 expression, whereas p65 knockdown ameliorated the
induction effects of TNF. These observations demonstrate that
IFN-induced LCN2 expression is largely mediated by STAT1
and that TNF requires NF-B to induce LCN2 expression in
adipocytes. There is some additional specificity in our observa-
tions as the knockdown of p65 also inhibited TNF-induced
MCP-1 expression, but STAT1 knockdown did not affect the
ability of IFN to induce MCP-1. It is not surprising that loss of
FIGURE 5. Regulation of the ERK signaling pathway and STAT1 and NF-B
serine phosphorylation by IFN and TNF. A, mature adipocytes were
treated with IFN (100 ng/ml), TNF (0.5 nM), or the combination of both
(Combo) for 15 min. Whole cell extracts were prepared, and 150 g of protein
was subjected to Western blot analysis. B, cells were treated with IFN (100
ng/ml), TNF (0.5 nM), or forskolin (FSK) (20 M) for 15 min. Whole cell extracts
were harvested, and 150 g of protein was analyzed by Western blot. C,
3T3-L1 adipocytes were treated with TNF (0.5 nM) or forskolin (20 M) for
16 h. Total RNA was isolated and subjected to real time PCR analysis. Cyclo-
philin A (PPIA) was used as an endogenous control. These data are from rep-
resentative experiments performed with three different batches of cells.
***, p  0.001. Error bars represent S.D. AU, arbitrary units; CTL, control.
FIGURE 6. Activation of ERKs is required for serine phosphorylation of
NF-B p65Ser536 and STAT1Ser727. A, 3T3-L1 adipocytes were pretreated
with 50 M ERK inhibitor UO126 for 30 min and then treated with 0.5 nM TNF
for 15 min. Whole cell extracts were isolated, and 150 g of protein was
analyzed by Western blot. B, adipocytes were treated with 100 ng/ml IFN or
0.5 nM TNF in the presence or absence of 50 M UO126. Whole cell extracts
were harvested, and 150 g of protein was subjected to Western blot analy-
sis. Data are from representative experiments that were independently per-
formed three times. CTL, control.
TABLE 2
STAT1 and NF-B binding sites in human lipocalin-2 promoter
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STAT1 or p65 did not completely abolish the induction
of LCN2 expression because siRNA-mediated knockdown of
these transcription factors reduced, but did not abolish, their
expression levels. Although LCN2 expression is likely affected
by other transcription factors, our observations strongly sug-
gest that STAT1 and p65 are critical for the induction of LCN2
by IFN and TNF.
Our previous studies on LCN2 revealed that ERK 1 and 2
signaling was required for the induction of LCN2 expression by
IFN and TNF in adipocytes (25). To follow up on these stud-
ies, we examined serine phosphorylation of STAT1 and the p65
subunit of NF-B. Some studies suggest that STAT1Ser727
phosphorylation contributes to the maximal transactivation
activity of STAT1 (30). The NF-B p65 subunit can be phos-
phorylated at Ser276 (29, 32) and Ser536 (27, 28). However, the
functions of these phosphorylated serines are controversial.
ERKs 1 and 2 are serine/threonine kinases activated by both
IFN (33) and TNF (34). We hypothesized that IFN- and
TNF-induced activation of ERKs may contribute to the serine
phosphorylation of both STAT1 and NF-B in adipocytes. Our
results clearly show that phosphorylation of STAT1Ser727 and
p65Ser536 was mediated by activation of ERKs 1 and 2. How-
ever, neither IFN nor TNF treatment affected phosphoryla-
tion of p65Ser276. As expected, the PKA activator forskolin
induced p65Ser276 phosphorylation, but it did not increase LCN2
expression. Forskolin treatment decreased LCN2 expression in
adipocytes. These results indicate that p65Ser276 phosphorylation
does not participate in the profound stimulatory effects of IFN
and TNF on LCN2 expression in adipocytes. The phosphoryla-
tion of p65Ser536 was induced by TNF but was not enhanced in
the presence of IFN. However, STAT1Ser727 phosphorylation
was much greater in the presence of IFN and TNF when
compared with individual cytokine treatments. Our study
also supports data showing that IFN-induced STAT1 serine
phosphorylation is not dependent on tyrosine phosphorylation
(35). Although we observed TNF-induced STAT1Ser727
phosphorylation, we did not observe any effect on STAT1
tyrosine phosphorylation under these conditions. There is
no doubt that the combination of IFN and TNF had a
cooperative effect on STAT1Ser727 phosphorylation and
LCN2 expression. Although TNF did not result in the tyro-
sine phosphorylation of STAT1, our results strongly suggest
that TNF induces ERK 1 and 2 phosphorylation of
STAT1Ser727 that mediates a cooperative effect between IFN
and TNF on LCN2 gene expression. It should be noted that
these cytokines can modulate other signaling proteins, and the
cooperative effects on LCN2 expression may be influenced by
ERK-independent pathways or other phosphorylation events.
However, based on our previous studies on LCN2 (25) and our
current results, we propose that STAT1Ser727 mediates cyto-
kine cooperativity and that there is minimal contribution from
other signaling pathways in the regulation of LCN2 in fat cells.
In summary, our study showed that the proinflammatory
cytokines IFN and TNF induce LCN2 expression and secre-
tion in vivo. The presence of both cytokines resulted in an addi-
tive effect on LCN2 expression. STAT1 was required for IFN-
induced LCN2 expression, whereas NF-B was necessary for
the induction of both LCN2 and MCP-1 by TNF. ERK signal-
ing appeared to contribute to the stimulatory effects of IFN
and TNF via modulating serine phosphorylation of STAT1
and the p65 subunit of NF-B. Four STAT1 binding sites and
one NF-B binding site were also identified in the human LCN2
promoter, which suggests that our observations have transla-
tional relevance. These studies provide insight into the ability of
proinflammatory cytokines to regulate adipocyte function.
Although the roles of LCN2 in insulin resistance are still
unclear, our mechanistic studies on LCN2 expression do
increase our understanding of the modulation of this adipokine
in conditions of obesity and type 2 diabetes.
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